An observational study in Periodontal Diseases and Periimplant Diseases, sponsored by Saglik Bilimleri Universitesi. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Saglik Bilimleri Universitesi · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Periodontal Diseases by Saglik Bilimleri Universitesi — 5 open to participants now, 5 under way, none of them phase 3. Periodontal Diseases · Saglik Bilimleri Universitesi.
Among the 10 studies in Periodontal Diseases by Saglik Bilimleri Universitesi, this one is one of 5 that started in 2026, is one of 8 observational ones, and was the 5th registered.
871 studies on the registry are indexed under Periodontal Diseases; 191 are open to participants now.
Browse Periodontal Diseases studies →5 of the 10 studies in Periodontal Diseases by Saglik Bilimleri Universitesi are open now, in 1 country. Recruiting first, the newest first:
Saglik Bilimleri Universitesi · Sites in Turkey
Ages 18+ · Healthy volunteers
Saglik Bilimleri Universitesi · Sites in Turkey
Ages 18–65 · Healthy volunteers
Saglik Bilimleri Universitesi
Ages 18–40 · Women only · Healthy volunteers
Saglik Bilimleri Universitesi
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
Of the 102 Periodontal Diseases studies recruiting now, 48 (47%) set no upper age limit and 42 (41%) stop at 75 or younger; 5 take children under 18; 59 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2022; this study’s year is marked. 5 started in 2026.
This study's planned enrollment of 80 is below the median of 100 across 304 observational studies indexed under Periodontal Diseases.
Median enrollment 23 across the 2 interventional studies, 80 across the 8 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Saglik Bilimleri Universitesi is the lead sponsor of 458 studies on the registry; 124 are open to participants now.
3 of the studies in Periodontal Diseases by Saglik Bilimleri Universitesi that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07146776Saglik Bilimleri UniversitesiTreatment of Intrabony Defects With Injectable Platelet-Rich Fibrin and Xenogenic Grafts | 2026-12-01 |
| NCT07699978Saglik Bilimleri UniversitesiMaternal Periodontal Inflammation and Pregnancy Outcomes: Salivary and Amniotic Biomarkers | 2027-03-15 |
| NCT07822269Saglik Bilimleri UniversitesiDental Loupe Versus Dental Operating Microscope for Non-Surgical Periodontal Treatment | 2027-08-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies in Periodontal Diseases by Saglik Bilimleri Universitesi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to evaluate and compare the levels of bone resorption (RANKL, OPG) and oxidative stress (Nitrotyrosine, NQO1) markers, along with pro-inflammatory cytokines (IL-1β), in the saliva and peri-implant sulcular fluid (PISF) of patients with peri-implantitis, periodontitis, and healthy individuals. The study seeks to determine the diagnostic value of these biomarkers in the early detection and progression of peri-implant diseases.
Patients applying to the University of Health Sciences, Gulhane Faculty of Dentistry, Department of Periodontology, will be screened according to the inclusion and exclusion criteria. Following clinical and radiographic examinations, participants will be categorized into four groups (n=20 per group): Periodontitis, Peri-implantitis, Periodontal Health, and Peri-implant Health. All clinical parameters, including Plaque Index (PI), Gingival Index (GI), Bleeding on Probing (BOP), Probing Depth (PD), and Clinical Attachment Loss (CAL), will be recorded at six sites per tooth/implant using a Williams periodontal probe.
The biological sample collection protocol will be conducted as follows:
Saliva Collection: To minimize circadian rhythm variations, unstimulated whole saliva samples (3 ml) will be collected between 9:00 AM and 10:00 AM. Patients will be instructed to refrain from eating, drinking, or oral hygiene procedures for at least one hour prior to collection. Samples will be centrifuged at 1,000g for 10 minutes to remove cellular debris, and the supernatant will be stored at -80°C until laboratory analysis.
Peri-implant Sulcular Fluid (PISF) and Gingival Crevicular Fluid (GCF) Collection: Samples will be obtained from the site with the deepest probing depth in each participant. The area will be isolated with cotton rolls and gently dried with an air syringe to prevent salivary contamination. Periopaper strips will be inserted into the sulcus/pocket for 30 seconds. Strips contaminated with blood or visible saliva will be discarded.
Laboratory Analysis: The concentrations of Interleukin-1 beta (IL-1β), Nitrotyrosine, Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL), Osteoprotegerin (OPG), and NAD(P)H: Quinone Oxidoreductase 1 (NQO1) will be quantified in both saliva and PISF/GCF samples using commercially available Enzyme-Linked Immunosorbent Assay (ELISA) kits according to the manufacturer's instructions.
Patients who apply to the University of Health Sciences, Gulhane Faculty of Dentistry, Department of Periodontology, and meet the specific clinical and radiographic criteria for peri-implantitis, periodontitis, or health.
Inclusion Criteria:
Systemically healthy volunteers aged 18-65. For Peri-implantitis group: Implants in function for ≥1 year, radiographic bone loss ≥ 2 mm, probing depth (PD) ≥ 5 mm, and presence of bleeding on probing (BOP) or suppuration.
For Periodontitis group: At least one tooth with PD ≥ 4 mm, presence of BOP, and radiographic bone loss.For Healthy groups: PD ≤ 3 mm, no clinical inflammation (BOP-), and no radiographic bone loss.
(According to the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases) -
Exclusion Criteria:Presence of systemic diseases (e.g., diabetes, rheumatoid arthritis, osteoporosis).
Use of antibiotics, anti-inflammatory, or drugs within the last 3 months.
Pregnancy or breastfeeding.
Smoking (current smokers).
History of periodontal or peri-implant surgical treatment within the last 6 months.
Implant failure (mobility).
Signs of acute infection (fever, systemic symptoms).
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with at least one dental implant in function for at least 1 year, showing signs of inflammation (BOP/suppuration), probing depth (PD) ≥ 5 mm, and radiographic bone loss ≥ 2 mm.
Patients with at least one tooth having clinical probing depth ≥ 4 mm, presence of bleeding on probing (BOP), and evidence of radiographic alveolar bone loss.
Patients with implants in function for at least 1 year, showing no signs of inflammation (no BOP), probing depth ≤ 3 mm, and no radiographic bone loss.
Systemically healthy individuals with clinical probing depths ≤ 3 mm, minimal plaque and bleeding scores, and no radiographic evidence of bone loss.
Salivary and Peri-implant Sulcular Fluid (PISF) IL-1β Levels.
The concentration of Interleukin-1 beta (IL-1β), a pro-inflammatory cytokine, will be measured in picograms per milliliter (pg/mL) using ELISA kits to evaluate the severity of inflammation and bone destruction.
Time frame: At the baseline clinical examination (Day 0).
Salivary and Peri-implant Sulcular Fluid (PISF) Nitrotyrosine Levels
Concentration of Nitrotyrosine will be measured in saliva and PISF samples using ELISA kits. Nitrotyrosine serves as a biochemical marker of nitrosative stress to evaluate oxidative damage.
Time frame: Baseline (at the time of clinical examination)
Salivary and Peri-implant Sulcular Fluid (PISF) NQO1 Levels
NAD(P)H: Quinone Oxidoreductase 1 (NQO1) levels will be measured using ELISA kits to assess the local and systemic antioxidant defense response.
Time frame: Baseline (at the time of clinical examination)
Salivary and Peri-implant Sulcular Fluid (PISF) RANKL Levels
Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) levels will be measured to evaluate osteoclast activation and bone destruction potential.
Time frame: Baseline (at the time of clinical examination)
Salivary and Peri-implant Sulcular Fluid (PISF) OPG Levels
Osteoprotegerin (OPG) levels will be measured. OPG acts as a decoy receptor for RANKL, and its level indicates the body's attempt to inhibit bone resorption.
Time frame: Baseline (at the time of clinical examination)
Clinical Attachment Loss (CAL) and Probing Depth (PD)
CAL and PD will be measured in millimeters (mm) at six sites per tooth/implant using a Williams periodontal probe to assess the severity of tissue destruction.
Time frame: Baseline (at the time of clinical examination)
Plaque Index (PI) and Gingival Index (GI)
PI and GI will be recorded using Silness-Löe and Löe-Silness indices (scored 0-3) to evaluate oral hygiene status and gingival inflammation.
Time frame: Baseline (at the time of clinical examination)
Plan to share: No — The individual participant data will not be shared to protect participant privacy.
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Nov 2026, 9 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 29, 2026: primary completion Aug 2026 → Nov 2026 and completion Sep 2026 → Nov 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Saglik Bilimleri Universitesi →